TOKYO and CAMBRIDGE, England, June 23, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) today announces that the first healthy subject has been dosed with HTL0022562 in a Phase ...
- Sosei Heptares will receive an upfront payment of US$10 million, plus downstream payments of up to US$370 million, plus tiered royalties TOKYO and CAMBRIDGE, England, Dec. 1, 2020 /PRNewswire/ -- ...
Zavegepant, an investigational nasal spray formulation of a small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist, met its co-primary endpoints in a phase III randomized ...
In 2011, Merck & Co. discontinued a once promising program to develop a new kind of drug to treat and prevent migraines. The biological rationale behind telcagepant—a small-molecule inhibitor of the ...
Initiation of a CGRP inhibitor was associated with a higher rate of the composite primary outcome than noninitiation (adjusted hazard ratio [aHR], 1.3; 95% CI, 1.1-1.45). It was also linked to an ...
BUFFALO, N.Y. — An estimated 1 billion people worldwide suffer from migraine headaches, which can cause nausea, severe pain and sensitivity to light and sound. But despite the high incidence of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results